Protective effect of TLR2/TLR9 agonists on pulmonary <italic style="font-style: italic">Acinetobacter baumannii</italic> infection in mice

Hao CHENG; Yun YANG; Hongwu SUN; Yan DENG; Guocheng LI; Jingwen CAO; Jing WEI; Yu CHI; Haibo LI

doi:10.16016/j.2097-0927.202401052

您当前的位置：

首页 >

文章列表页 >

Protective effect of TLR2/TLR9 agonists on pulmonary Acinetobacter baumannii infection in mice

Basic Medicine | 更新时间：2026-01-09

- Protective effect of TLR2/TLR9 agonists on pulmonary Acinetobacter baumannii infection in mice
- Journal of Army Medical University Vol. 46, Issue 8, Pages: 829-836(2024)
- 作者机构：
  
  1.400038 重庆，陆军军医大学(第三军医大学)药学与检验医学系微生物与生化药学教研室，国家免疫生物制品工程技术研究中心
  2.154007 黑龙江佳木斯，佳木斯大学临床医学院
- 作者简介：
- 基金信息：
  
  the General Program of National Natural Science Foundation of China(32270988)
- DOI：10.16016/j.2097-0927.202401052
  CLC： R517.9;R563.1;R977.6
- Received：14 January 2024，
  
  Revised：2024-01-29，
  
  Published：30 April 2024
- 稿件说明：
移动端阅览
Hao CHENG, Yun YANG, Hongwu SUN, et al. Protective effect of TLR2/TLR9 agonists on pulmonary Acinetobacter baumannii infection in mice[J]. Journal of Army Medical University, 2024, 46(8): 829-836.
DOI：

Hao CHENG, Yun YANG, Hongwu SUN, et al. Protective effect of TLR2/TLR9 agonists on pulmonary Acinetobacter baumannii infection in mice[J]. Journal of Army Medical University, 2024, 46(8): 829-836. DOI： 10.16016/j.2097-0927.202401052.

摘要

目的

评价toll-like receptor(TLR)2/TLR9激动剂对肺部感染鲍曼不动杆菌(

Acinetobacter baumannii

Ab)小鼠的保护作用。

方法

将6~8周龄雌性C57小鼠分为PBS组、Pam

CSK

(Pam)组、CpG ODN(CpG)组和Pam+CpG组，以不同剂量滴鼻免疫后24 h进行Ab肺部致死性感染，观察小鼠生存率。构建亚致死剂量Ab肺部感染模型，测定感染后小鼠血液、肺脏、肝脏、肾脏和脾脏的细菌定植量，并取小鼠肺脏和肾脏进行HE染色，分析病理损伤程度。探索免疫1、3、7 d后对小鼠Ab感染的保护作用，明确保护时间窗。Pam+ CpG体外刺激A549上皮细胞和RAW264.7细胞，考察两种细胞对Ab的杀伤或吞噬作用。

结果

与PBS组比较，Pam+CpG组能显著提高Ab致死感染小鼠的生存率(

0.05，

0.01)，降低亚致死感染后小鼠血液(

0.01)、肺脏(

0.01)、肝脏(

0.05)、肾脏(

0.01)和脾脏(

0.01)的细菌定植量，减轻感染导致的病理损伤；在感染之前1 d或3 d免疫均可显著提高小鼠的生存率(

0.05)，其中免疫后3 d保护效果最好。与PBS、Pam、CpG组比较，Pam+CpG组可以显著促进A549上皮细胞和R AW264.7细胞对Ab的杀伤或吞噬作用(

0.01)。

结论

TLR2/TLR9激动剂合用对Ab致死和亚致死感染均具有显著的保护作用，可能的机制是其促进了肺上皮细胞和巨噬细胞对Ab的杀伤或吞噬作用。

Abstract

Objective

To investigate the protective effect of Tol

l-like receptor (TLR) 2 /TLR9 agonists

Pam

CSK

(Pam) and CpG ODN (CpG) on mice infected with

Acinetobacter baumannii

(Ab) in the lungs.

Methods

Female C57 mice (6~8 weeks old) were randomly divided into PBS

Pam

CpG and Pam+CpG groups. In 24 h after intranasal immunization with different doses of the corresponding agonists

the mice were given a lethal dose of Ab infection in the lungs

and the survival rates of the mice were observed. A sublethal dose lung infection model of Ab was then established

and the bacterial colonization in the blood

lungs

liver

kidneys and spleen was measured respectively in the mice after infection. HE staining was used to observe the pathological damages in the lungs and kidneys. The protective effect of the agonists in the immunized mice against Ab was examined at 1

3 and 7 d after immunization to explore the protective time window. Pam+CpG was used to stimulate A549 cells and RAW264.7 cells to investigate the killing or phagocytic effects on Ab.

Results

Compared to PBS

Pam+CpG treatment significantly improved the survival rate of the mice after a lethal dose of Ab lung infection (

0.05

0.01)

reduced bacterial colonization in the blood (

0.01)

lungs (

0.01)

liver (

0.01)

kidneys (

0.01) and spleen (

0.01) in the mice after sublethal challenge

and alleviated pathological damage caused by infection. Immunization at 1 or 3 d before infection significantly improved the survival rate (

0.05)

and the protective effect was the best in 3 d after immunization. Furthermore

compared to single PBS

Pam and CpG immunization

Pam+CpG significantly promoted the killing and phagocytic effects of A549 epithelial cells and RAW264.7 cells

respectively

against Ab (

0.01).

Conclusion

Combined application of TLR2/TLR9 agonists exerts a significant protective effect on both lethal and sublethal infections of Ab

which might be by its promoting the killing or phagocytic effect of lung epithelial cells and macrophages against Ab.

关键词

Keywords

references

YANG N, JIN X, ZHU C, et al. Subunit vaccines for Acinetobacter baumannii [J ] . Front Immunol, 2023, 13: 1088130. DOI: 10.3389/fimmu.2022.1088130..

MCCONNELL M J, ACTIS L, PACHÓN J. Acinetobacter baumannii : human infections, factors contributing to pathogenesis and animal models[J ] . FEMS Microbiol Rev, 2013, 37(2): 130-155. DOI: 10.1111/j.1574-6976.2012.00344.x.

AYOUB MOUBARECK C, HAMMOUDI HALAT D. Insights into Acinetobacter baumannii : a review of microbiological, virulence, and resistance traits in a threatening nosocomial pathogen[J ] . Antibiotics, 2020, 9(3): 119. DOI: 10.3390/antibiotics9030119.

JEFFREYS S, CHAMBERS J P, YU J J, et al . Insights into Acinetobacter baumannii protective immunity[J ] . Front Immunol, 2022, 13: 1070424. DOI: 10.3389/fimmu.2022.1070424..

AFEKE I, ADU-AMANKWAAH J, NYARKO M, et al . Acinetobacter baumannii -induced infective endocarditis: new insights into pathophysiology and antibiotic resistance mechanisms[J ] . Future Microbiol, 2022, 17: 1335-1344. DOI: 10.2217/fmb-2021-0279..

EVANS B A, HAMOUDA A, AMYES S G B. The rise of carbapenem-resistant Acinetobacter baumannii [J ] . Curr Pharm Des, 2013, 19(2): 223-238. DOI: 10.2174/138161213804070285.

MA C Y, MCCLEAN S. Mapping global prevalence of Acinetobacter baumannii and recent vaccine development to tackle it[J ] . Vaccines, 2021, 9(6): 570. DOI: 10.3390/vaccines9060570.

2022年全国细菌耐药监测报告(简要版). [EB/OL ] . [2023-11-20 ] . https://www.carss.cn/Report/Details?aId=917 https://www.carss.cn/Report/Details?aId=917 .

National bacterial drug resistance surveillance report 2022(Brief Version). [EB/OL ] . [2023-11-20 ] . https://www.carss.cn/Report/Details?aId=917 https://www.carss.cn/Report/Details?aId=917 .

GELLINGS P S, WILKINS A A, MORICI L A. Recent advances in the pursuit of an effective Acinetobacter baumannii vaccine[J ] . Pathogens, 2020, 9(12): 1066. DOI: 10.3390/pathogens9121066.

TAN Y C, LAHIRI C. Promising Acinetobacter baumannii vaccine candidates and drug targets in recent years[J ] . Front Immunol, 2022, 13: 900509. DOI: 10.3389/fimmu.2022.900509.

KAUR A, BALDWIN J, BRAR D, et al . Toll-like receptor (TLR) agonists as a driving force behind next-generation vaccine adjuvants and cancer th erapeutics[J ] . Curr Opin Chem Biol, 2022, 70: 102172. DOI: 10.1016/j.cbpa.2022.102172.

ASHHURST A S, JOHANSEN M D, MAXWELL J W C, et al . Mucosal TLR2-activating protein-based vaccination induces potent pulmonary immunity and protection against SARS-CoV-2 in mice[J ] . Nat Commun, 2022, 13(1): 6972. DOI: 10.1038/s41467-022-34297-3.

DELIYANNIS G, WONG C Y, MCQUILTEN H A, et al . TLR2-mediated activation of innate responses in the upper airways confers antiviral protection of the lungs[J ] . JCI Insight, 2021, 6(5): e140267. DOI: 10.1172/jci.insight.140267.

LAI C Y, YU G Y, LUO Y P, et al . Immunostimulatory activities of CpG-oligodeoxynucleotides in teleosts: Toll-like receptors 9 and 21[J ] . Front Immunol, 2019, 10: 179. DOI: 10.3389/fimmu.2019.00179.

TUVIM M J, GILBERT B E, DICKEY B F, et al . Synergistic TLR2/6 and TLR9 activation protects mice against lethal influenza pneumonia[J ] . PLoS One, 2012, 7(1): e30596. DOI: 10.1371/journal.pone.0030596.

TAN A C L, MIFSUD E J, ZENG W G, et al . Intranasal administration of the TLR2 agonist Pam2Cys provides rapid protection against influenza in mice[J ] . Mol Phar, 2012, 9(9): 2710-2718. DOI: 10.1021/mp300257x.

GOLDBLATT D L, FLORES J R, VALVERDE HA G, et al . Inducible epithelial resistance against acute Sendai virus infection prevents chronic asthma-like lung disease in mice[J ] . Br J Pharmacol, 2020, 177(10): 2256-2273. DOI: 10.1111/bph.14977.

LI Y M, LIU L B, XIAO C L, et al . Outer membrane protein A of Acinetobacter baumannii regulates pulmonary inflammation through the TLR2-NF-κB pathway[J ] . Vet Microbiol, 2023, 284: 109812. DOI: 10.1016/j.vetmic.2023.109812..

KIM C H, KIM D J, LEE S J, et al . Toll-like receptor 2 promotes bacterial clearance during the initial stage of pulmonary infection with Acinetobacter baumannii [J ] . Mol Med Rep, 2014, 9(4): 1410-1414. DOI: 10.3892/mmr.2014.1966..

YAN J, NIELSEN T B, LU P, et al . A protein-free vaccine stimulates innate immunity and protects against nosocomial pathogens[J ] . Sci Transl Med, 2023, 15(716): eadf9556. DOI: 10.1126/scitranslmed.adf9556.

LEIVA-JUAREZ M M, KIRKP ATRICK C T, GILBERT B E, et al . Combined aerosolized Toll-like receptor ligands are an effective therapeutic agent against influenza pneumonia when co-administered with oseltamivir[J ] . Eur J Pharmacol, 2018, 818: 191-197. DOI: 10.1016/j.ejphar.2017.10.035.

ISIGI S S, PARSA A D, ALASQAH I, et al . Predisposing factors of nosocomial infections in hospitalized patients in the United Kingdom: systematic review[J ] . JMIR Public Health Surveill, 2023, 9: e43743. DOI: 10.2196/43743.

WEN R L, LI X Y, LIU T T, et al . Effect of a real-time automatic nosocomial infection surveillance system on hospital-acquired infection prevention and control[J ] . BMC Infect Dis, 2022, 22(1): 857. DOI: 10.1186/s12879-022-07873-7.

BOSE R J, KIM M, CHANG J H, et al . Biodegradable polymers for modern vaccine development[J ] . J Ind Eng Chem, 2019, 77: 12-24. DOI: 10.1016/j.jiec.2019.04.044.

JOHNSTONE C, CHAVES-POZO E. Antigen presentation and autophagy in teleost adaptive immunity[J]. Int J Mol Sci, 2022, 23(9): 4899. DOI: 10.3390/ijms23094899.

LAU Y T, TAN H S. Acinetobacter baumannii subunit vaccines: recent progress and challenges[J ] . Crit Rev Microbiol, 2023: 1-16. DOI: 10.1080/1040841x.2023.2215303.

NETEA M G, DOMÍNGUEZ-ANDRÉS J, BARREIRO L B, et al . Defining trained immunity and its role in health and disease[J ] . Nat Rev Immunol, 2020, 20(6): 375-388. DOI: 10.1038/s41577-020-0285-6.

BAEK H, CHO M, KIM S, et al . Analysis of length of hospital stay using electronic health records: a statistical and data mining approach[J ] . PLoS One, 2018, 13(4): e0195901. DOI: 10.1371/journal.pone.0195901.

GONG X X, ZHAO Q, WU Y F, et al . Mucoid Acinetobacter baumannii enhances anti-phagocytosis through reducing C3b deposition[J ] . Front Med, 2022, 9: 879361. DOI: 10.3389/fmed.2022.879361..

Views

135

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Risk factors for pulmonary infection in patients with acute cerebral infarction

Comparison of different adjuvants for immune efficacy of recombinant PKF protein of Acinetobacter baumannii

Establishment and preliminary application of a rapid pathogen-specific phenotypic antibiotic susceptibility test for Acinetobacter baumannii

Sub-minimal inhibitory concentration of imipenem enhances biofilm formation of resistant Acinetobacter baumannii isolates by affecting type Ⅳ pili

Prospect for vaccines to prevent superbug infection

Related Author

Minghao YUAN

Wenyu ZHANG

Ning ZOU

Qi LI

Xinyue QIN

Yingying GAO

Haibo LI

Jingyi LIU

Related Institution

Department of Neurology, the First Affiliated Hospital of Chongqing Medical University

Department of Microbiology and Biochemical Pharmacy, National Engineering Technology Research Center for Immune Biological Products, Faculty of Pharmacy and Laboratory Medicine, Army Medical University (Third Military Medical University)

Department of Pharmacy, First Affiliated Hospital, Army Medical University (Third Military Medical University)

Department of Microbiology and Biochemical Pharmacy, National Engineering Technology Research Center of Immunobiologics, Faculty of Pharmacy and Laboratory Medicine, Army Medical University (Third Military Medical University)

⁰

Protective effect of TLR2/TLR9 agonists on pulmonary Acinetobacter baumannii infection in mice

DOI：10.16016/j.2097-0927.202401052

摘要

Abstract

关键词

Keywords

references